NeuroStar TMS Outcomes Registry

The NeuroStar TMS Outcomes Registry has evaluable data on over 5200 patients since being initiated in Sept 2016, making it the largest data set in Major Depressive Disorder.

In these real-world outcomes, by clinician rating (CGI-S) 73% of patients respond to an acute course of NeuroStar, and 52% achieve remission.

On a patient rated scale (PHQ-9) 62% of patients achieved response and 33% achieved remission with an acute course of NeuroStar.

NeuroStar Outcome Registry and Star*D Study

Demographics and Clinical Characteristics

The NeuroStar TrakStar data management system makes automated large-scale data collection feasible.

These treatment outcomes are consistent with NeuroStar open-label study data5.

NeuroStar® Advanced Therapy has shown high-maintained response rates and remission rates. It has been widely researched with clinical data in more than 900 patients over 11 studies.1 This includes:

  • Results in 24 publications
  • 2 randomized, controlled trials
  • 1 large real-world trial
  • 12-month durability data

NeuroStar is the only system with acute treatment response and remission for over 1 year.19 Additionally, clinical studies showed a low discontinuation rate of only 5%.6,7

Have a representative contact you to learn how you can become part of a growing community of providers who are demonstrating real-world success. NeuroStar has been used on more than 80,000 patients across more than 3 million treatment sessions. There are more than 800 systems installed across the United States with thousands of trained physicians and clinicians providing therapy.

Hear from physicians and patients who’ve experienced success with NeuroStar